Finanzen von Zevra Therapeutics Inc (ZVRA)ZVRAZevra Therapeutics Inc

Evaluating the bottom line, Zevra Therapeutics Inc maintains a gross margin of 95.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 42.30%, while the net margin is 22.07%. These profitability ratios, combined with a Return on Equity (ROE) of 34.19%, provide a clear picture of how effectively ZVRA converts its operational activities into shareholder value.

In the context of the broader market, ZVRA competes directly with industry leaders such as IRWD and ASMB. With a market capitalization of $672.22M, it holds a significant position in the sector. When comparing efficiency, ZVRA's gross margin of 95.36% stands against IRWD's 100.00% and ASMB's 100.00%. Such benchmarking helps identify whether Zevra Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Zevra has shown strong revenue growth, reporting $39.7 million in Q2 2026, a 53% year-over-year increase, primarily driven by MIPLYFFA sales. The gross margin for Q2 2026 is 95.36%, indicating strong profitability in its core product. However, net income remains volatile, with a net income of $8.39 million in Q2 2026, following a significant loss in previous quarters.